Literature DB >> 8416442

Management of severe ovarian hyperstimulation syndrome by ascitic fluid aspiration and intensive intravenous fluid therapy.

M A Aboulghar1, R T Mansour, G I Serour, M A Sattar, Y M Amin, I Elattar.   

Abstract

OBJECTIVE: To assess the value of intensive intravenous (IV) fluid therapy and ascitic fluid aspiration in the management of severe ovarian hyperstimulation syndrome.
METHODS: Forty-two women with severe ovarian hyperstimulation syndrome were treated by ultrasonically guided transvaginal aspiration of ascitic fluid and IV fluid infusion. Ten women with the same condition treated conservatively constituted a comparison group. The main outcome measures included percentage change in hematocrit, creatinine clearance, and urine output before and after aspiration. The duration of hospital stay was compared between the groups.
RESULTS: Marked improvement of symptoms and general condition followed soon after aspiration. Hematocrit readings decreased by 22%, creatinine clearance increased by 79.3%, and urine output increased by 220.7%. The average volume of aspirated fluid was 3900 mL. The average duration of hospital stay was 3.8 days in the treated women. In the comparison group, severe symptoms and electrolyte imbalance continued for an average of 9 days, and the average hospital stay was 11 days.
CONCLUSION: Intensive IV fluid therapy and transvaginal aspiration of ascitic fluid are safe and effective in improving symptoms, preventing complications, and shortening the hospital stay in severe ovarian hyperstimulation syndrome.

Entities:  

Mesh:

Year:  1993        PMID: 8416442

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

1.  Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.

Authors:  Stephen R Lincoln; Michael S Opsahl; Keith L Blauer; Susan H Black; Joseph D Schulman
Journal:  J Assist Reprod Genet       Date:  2002-04       Impact factor: 3.412

Review 2.  Safety of drugs used in assisted reproduction techniques.

Authors:  Talha Al-Shawaf; Ariel Zosmer; Martha Dirnfeld; Gedis Grudzinskas
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: "tap early and often" versus hospitalization.

Authors:  John M Csokmay; Belinda J Yauger; Melinda B Henne; Alicia Y Armstrong; John T Queenan; James H Segars
Journal:  Fertil Steril       Date:  2008-11-05       Impact factor: 7.329

Review 4.  The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome.

Authors:  Lisa C Grossman; Konstantinos G Michalakis; Hyacinth Browne; Mark D Payson; James H Segars
Journal:  Fertil Steril       Date:  2010-09       Impact factor: 7.329

5.  Successful outcome of severe ovarian hyperstimulation syndrome (OHSS) with 27 liters of ascitic fluid removed by paracentesis.

Authors:  D Grochowski; E Sola; M Kulikowski; W Kuczyński; S Wołczyński; M Szamatowicz
Journal:  J Assist Reprod Genet       Date:  1995-07       Impact factor: 3.412

Review 6.  VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.

Authors:  Nikita Naredi; Pankaj Talwar; K Sandeep
Journal:  Med J Armed Forces India       Date:  2012-09-11

Review 7.  Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.

Authors:  Klaus Fiedler; Diego Ezcurra
Journal:  Reprod Biol Endocrinol       Date:  2012-04-24       Impact factor: 5.211

8.  Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.

Authors:  George T Lainas; Efstratios M Kolibianakis; Ioannis A Sfontouris; Ioannis Z Zorzovilis; George K Petsas; Theoni B Tarlatzi; Basil C Tarlatzis; Trifon G Lainas
Journal:  Reprod Biol Endocrinol       Date:  2012-08-31       Impact factor: 5.211

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.